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ONCOLOGY DIALYSIS PARENTERAL NUTRITION
TauroLock™ prevents catheter infections:
 
Catheter lock solutions are instilled into central 
venous access systems to have certain effects in 
this location. These access systems can be either 
dialysis catheters, Hickman- type lines or port-a-cath 
systems. The latter are used mainly in parenteral 
nutrition and for the administration of medication 
in oncology patients. These access systems are 
approved as medical devices and  are CE marked. 
The central venous access is inserted in the 
subclavian, jugular or femoral veins.
The use of Antimicrobial Lock Solutions have 
been recommended  in the “Hygiene Guideline 
complementing the German Dialysis Standard” and 
in the Position statement of European Renal Best 
Practice (ERBP)”. Pure heparin solutions containing 
no antimicrobial agent do not meet this criterion. 
Antibiotics are associated with the development 
of resistancy which is a major drawback. Highly 
concentrated citrate solutions and taurolidine-
citrate solutions are therefore conceivably useful in 
this application.
TauroLock™ is safe: 
TauroLock™ is biocompatible and non toxic. In contrast to highly concentrated citrate there is no protein precipitation if using TauroLock™****.
* Punt, C.D., Boer, W.E. Cardiac arrest following injection of concentrated trisodium citrate, Clinical Nephrology, 2008, 69: 117-118. ** Willicombe, M.K., Vernon, K., Davenport, A. Embolic Complications From Central Venous Hemodialysis 
Catheters; Used With Hypertonic Citrate Locking Solutions, American Journal of Kidney Diseases, 2010, 55: pp 348 - 351. *** Polaschegg, H.-D., Sodemann, K. Risks related to catheter locking solutions containing concentrated citrate,
Nephrol. Dial. Transplant. 2003, 18: 2688-2690. **** Schilcher, G. Polaschegg H.D. et al. Hypertonic Trisodium Citrate Induces Protein Precipitation in Hemodialysis Catheters, Selected ASN Meeting Abstracts, 2011
Antimicrobial Catheter Lock Solutions
Rollex Group Australia Pty Ltd
NSW, QLD, ACT & WA Sales Office:
11 Vangeli Street, Arndell Park NSW 2148 
VIC, SA, TAS & NT Sales Office
3/16 Curie Court, Seaford VIC 3198
Ph: 1300 880 441   |   Fax: 1300 880 451
Mobile: 0413 556 848
Email: dpashuwala@rollexmedical.com
Highly concentrated citrate solutions (30% and 
46.7%) cause major adverse effects such as 
cardiac arrests and embolisms that are a 
significant risk for the patient. TauroLock™ as an 
antimicrobial lock solution has proven useful in 
dialysis, oncology and parenteral nutrition for 
many years and has meanwhile become 
established in the prevention of catheter-related 
infections.  
The requirements of antimicrobial 
catheter lock solutions:
What should they do and what 
can they do? 
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Abstract
Background
Nurse-assisted automated peritoneal dialysis (AAPD) offers a model of care that has been successfully used in frail 
dialysis populations internationally. AAPD offers cost savings over hospitalisation on peritoneal dialysis (PD) or in-centre 
haemodialysis (HD).
Method
A pilot AAPD model of care was developed in Western Australia (WA). Patient evaluation was measured utilising 
a perceptions of dialysis survey, clinical events, hospitalisation and peritonitis rates, Charlson Comorbidity Index 
(CCI), KDQoL-SF 36 and a survey. Staff opinions and perceived competency were measured by an online survey. 
Economic analysis was undertaken.
Results
A successful collaborative model was developed. 40 staff were trained and competency significantly improved during 
program delivery (p<0.0001). 15 patients with an average CCI score of 8.7 used the service for 18 periods of care 
over 18 months (mean 33 days SD 47). Two non-renal cause deaths and two episodes of peritonitis occurred. Patient 
opinions were extremely positive. Cost savings were estimated at $620,000.
Conclusion
In WA, an AAPD pilot program has been successfully developed and delivered. A sustainable model has overcome 
initial hurdles. Staff have gained new skills and delivered effective care, demonstrated by high patient acceptance. The 
program was cost-effective compared to staying in hospital or transferring to HD.
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patient to a cycler, patient assessment, disconnecting from a 
cycler, or performing continuous ambulatory peritoneal dialysis 
(CAPD) exchanges (Dimkovic et al., 2009; Lyasere et al., 2016).
Internationally, AAPD is highly successful (Brown & Vardhan, 
2011; Li, 2008; Lyasere et al., 2016; Querido et al., 2015). 
In France, where AAPD programs have existed for many 
decades, registry data has demonstrated that 56% of patients 
>70 years old were considered unable to independently 
perform PD, with assistance successfully provided by visiting 
nursing staff in 86% of cases (Lobbedez et al., 2006; Verger 
et al., 2006). In Toronto, the AAPD program has increased 
the proportion of patients considered eligible for PD and has 
proven cost-effective, being highly valued by patients and staff 
(Oliver & Quinn, 2009). Although AAPD programs cost money, 
the cost differential between PD and HD is more than the cost 
expended (Franco et al., 2012; Health Policy Analysis Pty Ltd, 
2009; Laplante et al.,2015).
There are many indications for AAPD. It can act as a bridge 
therapy when either an intervening illness makes it temporarily 
difficult to continue on PD, or someone is waiting to train for 
PD (Povlsen & Ivarsen, 2007). In those that develop permanent 
barriers to self-care dialysis, the provision of assistance can 
avert PD technique failure and a forced switch to in-centre HD 
(Brown & Wilkie, 2016).
AAPD can also provide respite for family-assisted APD to help 
carers maintain employment and decrease burnout (Brown 
& Wilkie, 2016; Brown & Vardhan, 2011; Povlsen & Ivarsen, 
2007). AAPD also provides reassurance to elderly persons and 
their families, alleviating the concern about family burden (Tong 
et al., 2013). For new patients, AAPD can be used as a form 
of ongoing training or mentoring that allows patients to gain 
confidence performing PD-related tasks in a supervised setting, 
where some patients eventually graduate to self-care PD (Oliver 
& Quinn, 2009).
Given all of the data there appears to be an opportunity for the 
development of ongoing AAPD programs in Australia. Notably, 
in 2014, 16% of Australian patients discontinued PD because 
of personal reasons, including inability to self-care (ANZDATA, 
2015). Anecdotally in WA, lengthy hospitalisations or transfers 
to HD were occurring related to the inability of a patient or 
family to manage AAPD due to acute illness (often physical 
injury or surgery), chronic deterioration in health, carer burnout 
and a delay in time to training.
AAPD has to fit into the service provision model. WA home 
dialysis services are corporatised, with partnership care divided 
between the hospital (inpatient service only) and the external 
provider, Fresenius Medical Care (FMC — outpatient service, 
including training and ongoing follow-up and management). 
There was no provision for AAPD or respite care.
Background
In recent years, there has been mounting evidence to suggest 
the use of home dialysis therapy is both beneficial to patients 
with end-stage kidney disease (ESKD) and cost-effective for 
the health care system when compared to traditional in-centre 
haemodialysis (HD) (George Institute, 2010). In Australia, 
30% of people on dialysis treatments self-care at home, with 
20% using peritoneal dialysis (PD) and 65% of these using 
automated peritoneal dialysis (APD) (ANZDATA, 2015). Country, 
policy and model of care influence dialysis modality prevalence 
and compared to some international practice Australia has 
opportunities to improve PD rates (Fortnum et al., 2012).
PD confers lifestyle advantages including; more time at home, 
reduced travel to/from the dialysis unit and more flexibility 
in dialysis regimes; as well as health advantages including 
better dialysis tolerance, improved health outcomes, reduced 
exposure to hospital pathogens and better quality of life, 
particularly for elderly patients. (Brown, 2011; Jager et al., 
2004). However, independent PD utilisation is on the decline 
in many regions around the world for many reasons, including 
an ageing and frail dialysis population (Oliver & Quinn, 2009). In 
Australia, 41% of incident and 49% of prevalent patients using 
PD are now over 65 years of age (ANZDATA, 2015).
Reported disease burden of ESKD patients includes vascular 
disease, reduced vision, deafness, poor mobility, often related 
to arthritis, and increasingly dementia and cognitive impairment 
(70% of those over 55) (Dimkovic et al., 2009). One study 
found that 25% of PD patients had visual impairment and 
20% had severe mobility impairment. (Oliver & Quinn, 2009). 
Assisted automated peritoneal dialysis (AAPD) has been 
demonstrated to overcome physical, cognitive, psychological 
or social barriers to enable patients to have PD, and can be 
long-term or short-term (Oliver & Quinn, 2009).
Australia clearly has an ageing population and planning 
is recommended to manage the growing health burden 
(Productivity Commission, 2013). Assisted PD is not new in 
Australia. Seventy per cent of PD patients already receive some 
assistance with their dialysis, from friends or family (Fortnum et 
al., 2015). However, the authors are only aware of two limited 
services in Australia for non-family AAPD: one a pilot study 
in Victoria delivered by the community nursing service and 
another service by Baxter Health Care in South Australia a 
number of years ago (unpublished).
Providing non-family AAPD involves identifying and training 
an employee to perform dialysis-related tasks. Public system 
nurses, private nurses, nursing aids and assistants have all 
been employed and trained successfully overseas (Brown & 
Wilkie, 2016; Oliver & Quinn, 2009; Povlsen & Ivarsen, 2007). 
The tasks may include setting up the cycler, connecting the 
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In 2014, it was identified that the Home Link nursing service at 
Sir Charles Gairdner Hospital (SCGH) offered an opportunity to 
develop a pilot, metropolitan-based AAPD program, modelled 
on a program at Manchester Royal Infirmary (Brown & Vardhan, 
2011). The Home Link nursing service has an objective to 
shorten length of stay in hospital (LoS), meaning that AAPD 
for previously hospitalised or about to be admitted patients fit 
under the service criteria. Of note, nursing home patients are 
excluded from the Home Link program.
Aim
This project sought to develop a sustainable AAPD model 
and also to assess current patients’ attitudes towards home 
dialysis, determine whether providing AAPD is cost-effective 
and measure the characteristics of the users and their quality 
of life. The aim was to run a one-year prospective research 
project as a pilot.
This paper focuses on the model development, nurse training 
and some clinical research results.
Method
The development of the AAPD program was a joint project 
between the external provider FMC, SCGH PD unit staff, Home 
Link, a lead nephrologist and the renal ward. As with all new 
programs, hospital permissions were sought. Funding was 
obtained through a State Health Research Advisory Grant 
(SHRAC).
To determine potential uptake of AAPD, a 28-question 
(multiple-choice format) paper-based perceptions of dialysis 
survey was offered to any current PD or HD patients at 
SCGH. Clinical evaluation of the AAPD service included a 
KDQoL-SF36, Charlson Comorbidity Index scores (CCI), 
clinical outcome measures and a structured phone survey of 
participant opinions (AAPD participants).
Costings were calculated using a cost-minimisation analysis 
approach. Home Link nurses could opt in to complete an 
online survey focused on their education and experience.
Other stakeholders underwent semi-structured interviews to 
determine strengths and weaknesses of the program and to 
allow future development of both the program and business 
plans.
The research component was ethics-approved (HREC 
reference 2014-149) and patients consented to take part. 
It was intended to have a control group of those who were 
eligible but did not consent to AAPD, but every eligible patient 
consented. Prism version 6.0b statistical software was used 
to perform frequency, means and chi-square tests. Qualitative 
responses were thematically analysed.
Results
Development of the AAPD program
The key areas were: 1. Development of pathways and roles; 
2. Staff training; 3. Policies and protocols 4. Research and 
evaluation.
1. Development of pathways and roles
Communication is central to any patient management process 
and the wide group of WA stakeholders meant the pathways 
and roles were critical. Alterations to contracts between the 
hospital and FMC were undertaken. Two key pathways were 
developed: one for patients already on APD and the second 
for those who were pre-training. Basic training and on-call for 
new patients was provided by the SCGH ward or PD staff. For 
those already on APD, this responsibility stayed with FMC.
2. Staff training
To provide continuous cover the decision was made to train all 
Home Link staff. They had previously received some theoretical 
training to facilitate administration of intra-peritoneal antibiotics. 
The training was conducted by FMC with a focus on practical 
machine skills because Home Link staffing time constraints 
limited the sessions to two hours. Following a demonstration, 
staff were supervised to perform skills but did not have 
competencies completed. They were provided with step-by-
step guides and Home Link facilitated a pairing or mentoring 
system to support initial home visits until staff and their mentor 
determined they were competent.
3. Policies, protocols and governance
Standard APD procedures were adapted for the program and 
key forms including a referral form were developed. It was 
determined that to be cost-effective the nurses could only visit 
once a day and this visit would involve patients’ assessment, 
machine strip-down and machine set-up. This led to one key 
change to policy — increasing the time delay allowed from 
set-up to connection, giving a wider range of visit times. The 
once-a-day policy also meant the patient or carer had to 
be able to perform the connection and disconnection. This 
was also considered a risk management mitigation policy 
ensuring patients could disconnect in the case of alarms or an 
emergency in the home.
Patient criteria also included a working PD catheter, willingness 
to consent, reasonable house condition and a phone. 
Categories of patients included pre-training requiring immediate 
dialysis and any short-term need for existing patients who 
would otherwise be hospitalised. Referrals could be made 
by all stakeholders and went via the lead nephrologist, who 
consented patients into the service and research.
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Governance and support for the new patients was hospital-led, 
whereas for respite patients FMC managed their ongoing PD-
related care.
4. Research and evaluation
Perceptions of dialysis survey
Fifty-three PD patients responded to the perceptions of dialysis 
survey and 60% indicated they would be willing to have AAPD 
by a paid external person as a permanent treatment choice. In 
a further question, 92% of responding PD patients would be 
willing to have a nurse manage their PD rather than transfer 
to HD if they were temporarily unable to remain independent 
(Fortnum & Chakera, 2017).
Participants
In 2015, 98 WA patients were using APD with 41 new patients 
trained in total. Forty-seven per cent of these were from 
SCGH. During 17 months of the pilot study, 18 referrals for 15 
individual patients occurred and 594 episodes of AAPD care 
were delivered. Table 1 shows the demographics. The key 
reasons for use of the service were acute injury/surgery, pre-
training, reduced capacity to manage PD post-hospitalisation 
and requested carer respite (Table 1). Two patients also 
received intraperitoneal drugs for existing peritonitis during their 
respite.
Clinical data and outcomes
The average patient had a high CCI of 8.7 (Table 1). The 
average score of those who have since died was 12.2, 
compared to 6.9 in those still alive. QoL scores were 
particularly low in physical health (27.5), mental health (35.2) 
and burden of kidney disease (25.0) domains (Table 1). KDQoL 
total scores did not correlate with CCI scores.
Seventy-eight per cent of patients resumed or started 
independent PD. Two respite patients deceased from 
myocardial infarction whilst on AAPD. Their age-adjusted 
CCI scores were 14 (metastatic cancer) and 7. One respite 
patient (CCI 16) contracted a gram-negative peritonitis and 
transferred to HD with a subsequent death due to metastatic 
cancer. Another respite patient with a previous six episodes of 
peritonitis in 11 months (history of dyscopia, depression and on 
Number (%) or mean (SD) Range Benchmark data
Male 11 (64%) 60% (ANZDATA)
Age (years) 68.9 (SD 9.0) 49–83 65 years (ANZDATA)
CCI (age-adjusted) 8.7 (SD 3.7) 3–16 4.3–7 (Lobbedez et al.)
KDQol-SF 36
Physical function — SF 12 27.5 (SD 5.3) 19–36 33 (Lyasere et al.)
Mental function — SF 12 35.2 (SD 9.9) 22–60 49 (Lyasere et al.)
Symptom/problem list 64.4 (SD 13.2) 31–85
Effects of kidney disease 49.6 (SD 18.9) 12–72
Burden of kidney disease 25.0 (SD 28.0) 6–93
PD data
Time on PD (weeks and respite 
only)
101 (SD 48) 22–150 63% of patients on PD at 
two years (ANZDATA)
Time spent on AAPD (days) 33 (SD 47) 1–143
Kt/V (closest date if not done 
during AAPD)
2.17 (SD 0.31) 1.56–2.64 Target 1.7 (ISPD)
Reason for referral
Pre-dialysis 5 (28%)
Acute injury/illness 
(self-care)
5 (28%)
Respite (carer) 3 (17%)
Post-hospital (self-care) 5 (28%)
Outcomes (total 21 patient months)
Death 2 (11%)
Started training 5 (28%)
Transfer to HD 2 (11%)
Resumed usual PD 9 (50%)
Peritonitis rate 1 in 11 months 1 in 18 (WA — ANZDATA)
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intermittent HD) contracted peritonitis and transferred to HD. 
There were no other episodes of hospitalisation.
Home Link nurses managed 14 documented health issues 
that were non-renal, with five resolved by the GP, five by liaison 
with the hospital and three sent to emergency departments. 
There were four renal issues with collaborative resolution and 
48 prescription queries with resolution managed by Home Link 
via FMC for established patients and via the hospital for new 
patients. Ten technical problems with dialysis were managed by 
Home Link staff in collaboration with FMC, but five did result in 
the patient missing a night of dialysis.
Ten patients (66%) answered the phone follow-up survey to 
determine quality and acceptability of AAPD delivered by Home 
Link. One had used the service twice. Ninety-one per cent 
rated the service as extremely important, 73% as excellent and 
27% as very good. One hundred per cent thought it should 
continue and would recommend the service. Respite periods 
of care ran more smoothly and rated higher than pre-training. 
Recommendations for change were minor and actionable.
Home Link nurses survey
Sixteen of 40 nurses responded (40%) to the survey: 10 
registered nurses, five clinical nurses and one other. Twenty-five 
per cent of nurses had less than 10 years’ experience and 44% 
had over 20 years’ experience. Eighty-seven per cent had none 
or little experience of PD.
Training included theoretical (68.8% attended group theory) 
and practical components (100%) — either simulated or in 
the home. Following initial group education sessions, 81% felt 
“just adequately” or “inadequately” skilled. However, they were 
provided with step-by-step guides and Home Link facilitated a 
pairing or mentoring system to support initial home visits, until 
staff and their mentor determined they were competent.
The mean average for care sessions delivered was 15 sessions 
(range 0 to over 20). In February 2017, 50% of staff felt 
“reasonably confident”, with 43.8% “completely confident” 
in care delivery. Delivering more than five sessions correlated 
strongly with current higher competence level p<0.0001. 
The skills that nurses felt most competent in were patient 
assessment (80%), seeking support (80%), setting up the 
machine (66.7%) and dismantling the machine (60%). One 
hundred per cent of staff felt that training refreshers should be 
held annually.
Satisfaction with delivering the service was high:
• 71.4% enjoyed delivering the AAPD care.
•  100% felt the skills were valuable to have learned “all” or 
“most of the time”.
•  78.6% felt it was a positive service for the patients “always” 
and the remainder for “most of the time”.
Practical aspects of the program were also evaluated and 
overall were positive:
•  The referral form met needs “always” for 14.3% of 
respondents and “most of the time” for 64.3%.
•  Policies and procedure met needs “always” for 35.7% and 
“mostly” for 57.1%.
•  Clinical support was adequate “always” for 50% and 
“mostly” for 57.1%.
•  Supplies were available “always” for 50% and “mostly” for 
50%.
All respondents thought it should be continued with expanded 
criteria including a long-term service and a broader catchment 
area. Additional general comments included “Life in hospital 
and with patients is never routine and one box does not fit all”. 
“Logistics of becoming an outpatient after being an inpatient 
are often complex.”
The final evaluation related to nursing care delivery assessed 
the support phone calls. FMC collected this data. Sixty-three 
phone calls (one per 10 visits) were documented with a mean 
time of 5.3 minutes (range 1–15 minutes). Forty per cent were 
for prescription enquiries, 34% for clinical PD issues and 20% 
for technical set up and support. There was an even split 
between calls being made during hours compared to out of 
hours.
Costing
In summary, the program delivery was found to be cost-
neutral for WA health, with Home Link being able to deliver 
the service for $274 per visit, and then reclaim this cost from 
the Commonwealth government (total claim of $162,756). To 
calculate the cost differential, patients were allocated to either 
staying in hospital or transferring to centre-based HD, based 
on their history and preferences and for the time they needed 
to use the AAPD service. The costs were compared to being 
on AAPD.
It was calculated that 518 bed days and the equivalent to 11 
weeks of centre-based dialysis were saved. Five hundred and 
ninety-four AAPD days were incurred. All dialysis, transport 
and overhead costs were included for each treatment option. 
Initial calculations estimate that by having the option of AAPD, 
rather than staying in hospital or transferring to HD, substantial 
savings were realised for WA Health (and the health system 
as a whole). This is as expected, given the cost differential 
between inpatient and outpatient care and home therapies 
versus in-centre HD.
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Discussion
The patient cohort included existing patients with acute injury, 
surgery, hospital deconditioning, carers being unavailable and 
new patients requiring urgent dialysis but on a waiting list to 
train. It strongly represented the anticipated cohort and those in 
programs overseas, although AAPD for the pre-training period 
was only found in one study (Povlsen & Ivarsen, 2007).
The goal of the WA program meant that the participants were 
dependent (requiring hospital bed days). Seventy per cent of 
the cohort was frail and unable to self-care for their PD due to 
either acute injury or hospital deconditioning. The CCI score 
average was 8.7. Comparable overseas cohorts scored 7.0 for 
assisted PD compared to 4.3 for self-care PD (Lobbedez et al., 
2006) and 6.8 for an AAPD cohort (Brown & Vardhan, 2011).
There are clinical differences in group KDQoL-SF36 scores in 
the literature but one similar study on AAPD patients recorded 
mean physical scores of 33 and mental scores of 49. They 
found comparable mental scores for HD patients, although 
AAPD patients had lower physical functioning than the HD 
population (Lyasere et al., 2016). These physical and mental 
scores reflect those found on the WA pilot program. Future 
data on frail HD patients for benchmarking would be useful.
Outcomes
One measure of AAPD program outcome benchmarking is 
peritonitis rates. Of note, due to both staffing constraints and 
safety concerns for emergency situations, WA participants had 
to self-connect, which rarely occurs in other programs and 
this limits outcome comparison. The programs detailed in the 
literature mention peritonitis rates, for example in Brazil it was 
1 per 37 patient months (Franco et al., 2012). As with our pilot, 
the small cohort and variable models in most programs makes 
it difficult to calculate reliable data or benchmark but there are 
no indications that peritonitis is a barrier for AAPD, particularly 
as there is little choice in therapy for most of this cohort.
It is also an important question as to whether morbidity or 
mortality are better on HD or AAPD. The WA study could not 
generate the control group because no one was rejected from 
program participation and sent to HD. Looking at international 
data, frailty has been identified to be the only real predictor for 
poor dialysis outcomes (p<0.0001) but no difference was found 
between matched groups of HD and AAPD patients (Brown & 
Wilkie, 2016; Lyasere et al., 2016). Brown and Vardhan (2011) 
reported similar mortality, hospitalisation and QoL scores 
for HD and PD patients in an elderly UK cohort. Brown and 
Vardhan (2011) reported high but acceptable hospitalisation 
rates in their frail population — mean time on AAPD 29–745 
days — (15 out of 24 patients hospitalised, with 13 of these 
patients in hospital 1–2 months).
Staff factors
Staff PD training will always be a “time and cost” versus 
“required knowledge” debate, particularly where large 
staff numbers are needed. The training time of two hours 
was relatively short for nurses unskilled in APD and this 
probably was reflected in their low self-reported post-training 
competence. For comparison, Povlsen and Ivarsen (2007) 
reported that their program delivers 2.5 hours of theory 
and 2.5 hours of practice to health care assistants prior to 
providing AAPD, benchmarking positively with international PD 
outcomes. The French program operates on a half-day training 
program, but the UK program provided three days of training 
by an external provider (Lobbedez et al., 2006; Povlsen & 
Ivarsen, 2007).
Staff support is also a critical factor to improve outcomes 
(Povlsen et al., 2007). The WA nurses operated a mentor 
support program and valued the support offered. This pilot also 
found that continuous exposure to delivery of care is key to 
long-term competency.
Models of care
There are multiple models to deliver AAPD. The models 
of care internationally depend on resources, varied health 
care models and funding models (Dimkovic et al., 2009). 
All published overseas models offer AAPD as an ongoing 
replacement therapy choice, not just an acute service (Brown 
& Wilkie, 2016). Consistencies throughout programs include 
on-call support, patient assessment and the desire to reduce 
hospitalisation and burden to HD units.
Some programs offer two visits a day and include 
disconnection and connection for APD, but still report cost-
savings over HD (Lobbedez et al., 2006). Most programs 
discuss an aim for independence and minimised visits if 
possible in the long-term, again to control costs. One program 
offered a dialysis free day per week on a Sunday (Brown & 
Wilkie, 2016; Lyasere et al., 2016). The WA program used 
only registered nurses, whereas many overseas programs 
use specifically employed nursing assistants to control costs 
(Dimkovic et al., 2009).
Both public and private nurses have been used, some already 
skilled but many not (Lobbedez et al., 2006). WA chose to 
deliver AAPD, whereas some countries prefer to support 
CAPD, which can remove the machine complexities. With 
CAPD to minimise staff time, the French program encourages 
some patient involvement to drain using non-disconnect 
systems or flash systems (Brown & Wilkie, 2016; Lobbedez et 
al., 2006).
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Sustainability
Sustainability relies on funding, staff skills and referrals. The 
funding source for Home Link nurses became sustainable by 
accessing a national health activity-based funding payment, 
the standard Tier 2 clinic non-admitted service funding ($275). 
Although AAPD has additional costs compared to standard 
APD the total cost is considerably less than in-centre HD at 
SCGH.
The staff skills are being maintained with a “train the trainer” 
mentor approach. Occasional retraining days are planned or 
new training days if there are significant numbers of new staff. 
Step-by-step procedures have also been developed. The 
success of the program is being advertised and expanded 
criteria for those using the program are being evaluated.
Conclusion
If AAPD can be offered as a cost-neutral or cost-saving service 
for dialysis patients compared to centre-based HD, then our 
pilot study and those of other countries suggest it is a viable 
model, meeting both the demands of health care systems and 
being positively accepted by patients and their families. It is 
important that data are collected and benchmarked to ensure a 
quality service.
A WA pilot of AAPD has been successful and continues to 
operate. A sustainable model has been developed, overcoming 
initial hurdles. Staff have gained new skills and delivered 
effective care, demonstrated by a high patient acceptance. The 
program was cost-effective compared to staying in hospital or 
transferring to HD.
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